YM BIOSCIENCES GRANTED TWO US PATENTS FOR AEROLEF ®
- Additional AeroLEF patents granted in Europe, China and other territories -
MISSISSAUGA, Canada - February 10, 2010 - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM),
announced that it has been granted two additional patents in the US for AeroLEF ® , the
Company’s proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in
development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981
and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024. The Company also
announced that AeroLEF’s patent estate has expanded to include other territories with the
issuance of European patent number 1,603,533 and several patent allowances in China, India,
Mexico and other territories.
“These patents strengthen and extend the patent protection for AeroLEF in the US, and also expand
the global market for this unique and potentially first in class product,” said David Allan, CEO of YM
BioSciences. “The scientific pedigree and unique advantages of this product have been
established and its safety and efficacy have been demonstrated in numerous clinical trials.
AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is
currently being prepared for late-stage development internationally.”
US patent number 7,648,981 protects the self-medicating method of pain management in which
the pain sufferer inhales a formulation comprising free and liposomal fentanyl in a dose ratio that
provides rapid onset and sustained relief from pain without attendant toxicity. Also claimed is a
breath-actuated device for delivering the fentanyl formulation.
US patent number 7,648,982 similarly covers a pain relief method and device that delivers fentanyl
formulations defined according to the particle sizes and unit doses effective to manage pain by the
route of pulmonary delivery. European patent number 1,603,533 and other rece